Regardless of whether you are a PvP player or a PvE player wanting to make an Arc build, this Destiny 2 Sidearm is a must ...
EMA committee recommends approval of Bristol Myers’ repotrectinib to treat advanced ROS1-positive NSCLC & NTRK-positive solid tumours: Princeton, New Jersey Monday, November 18, ...
A fusion reactor promises almost limitless energy—if we can build it. Physicist Tammy Ma explains how her team achieved ...
Boston Pharmaceuticals has linked its metabolic dysfunction-associated steatohepatitis (MASH) prospect to improved outcomes ...
DelveInsight's 'Multiple Sclerosis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline multiple ...
Company remains on track in late-stage, potentially registrational trials of nemvaleukin alfa, with data readouts expected in late Q1/early Q2 ...
Tectonic Therapeutic to present positive phase 1a results of TX45, a long-acting, Fc-relaxin fusion protein at AHA 2024: Watertown, Massachusetts Tuesday, November 12, 2024, 13:00 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback